Our 15% discordance rate in CTCs of patients with operable breast cancer is lower than those reported by Ignatiadis et al. and Apostolaki et al., who found discordance rates of 28–44% in patients with operable breast cancer using RT-PCR to evaluate HER2 status of CTCs 14,15. Here, ERBB2 is linked to breast cancer.